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ABSTRACT
Background. The antiangiogenic drug sorafenib has been
shown to be an effective treatment for hepatocellular car-
cinoma (HCC) in patients with liver cirrhosis. It might also
be effective in noncirrhotic HCC provided that the angio-
genic properties of both tumor types are comparable. The
aim of this study is to compare endothelial cell dynamics,
microvessel density (MVD), and vessel maturation as
indirect markers of angiogenesis in human HCC in cir-
rhotic and noncirrhotic livers.
Materials and Methods. In a tertiary care setting, 70
consecutive HCC tumors were analyzed for endothelial cell
dynamics. CD34 was applied to identify tumor microves-
sels, double immunolabeling Ki67/CD34 and activated
caspase-3/CD34 to assess endothelial cell proliferation and
apoptosis, and a-smooth muscle actin/CD34 for pericyte
coverage. These characteristics were compared in cirrhotic
(n = 33) and noncirrhotic HCCs (n = 37). Microvessel
density was correlated with radiological signs of hyper-
vascularity as obtained with dynamic four-phase CT scans
during the arterial and portal phase of contrast
enhancement.
Results. Microvessels in cirrhotic and noncirrhotic HCC
were mainly mature. In both groups endothelial cell turn-
over was low and MVD was not different. There was no
correlation between MVD and venous invasion, tumor size,
and turnover of tumor cells or endothelial cells. MVD was
negatively correlated with contrast washout in the portal
venous phase of CT scanning. In transplanted patients,
MVD was not correlated with survival, whereas in patients
after liver resection a high MVD was associated with a
better prognosis.
Conclusion. Angiogenic characteristics of HCC in cir-
rhotic and noncirrhotic livers have a remarkable similarity.
Hepatocellular carcinoma (HCC) generally develops in
cirrhotic livers. The various underlying chronic liver dis-
eases that result in cirrhosis have a variable incidence of
HCC development.
1 Viral hepatitis B and C (HBV, HCV)
are among the most frequent causes of HCC worldwide.
The risk of developing HCC is dependent on the epide-
miology of viral hepatitis and alcohol consumption.
2
Chronic inﬂammation in the cirrhotic liver induces archi-
tectural and functional changes that result in hypoxia, one
of the most potent stimuli for angiogenesis.
3 HCC very
rarely develops in patients with normal liver histology
(thus without liver cirrhosis) and without underlying viral
hepatitis. In contrast to patients with HCC in cirrhotic
livers, patients with noncirrhotic HCC often present in
advanced stages because they are not participating in
screening programs. Additionally, they often do not qualify
for liver transplantation because of the large size of the
tumors. Recurrence rates of up to 40% after partial liver
resection are reported.
4
HCC is a highly vascularized tumor and has a pre-
dominant arterial supply that can be demonstrated by
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angiography in which hyperattenuation is obtained in the
arterial phase and hypoattenuation in the portal phase.
5
Arterial hypervascularization is one of the diagnostic cri-
teria of HCC in cirrhotic patients.
6 It is assumed that
hypervascularization as seen on imaging techniques cor-
relates with angiogenesis.
7
Angiogenesis is characterized by destabilization of
existing vessels, endothelial cell (EC) proliferation, and
vessel sprouting, followed by stabilization of the newly
formed vessels.
8 Because of this, many antiangiogenic
treatments target VEGF, which is a crucial growth factor
for EC proliferation.
9 The results of the SHARP trial
demonstrate a nearly 3-month survival advantage in those
cirrhotic patients with HCC who were treated with so-
rafenib.
10 One of the working mechanisms of sorafenib is
inhibition of neoangiogenesis by inhibition of the vascular
endothelial growth factor receptors (VEGFR).
11 It is
unknown whether HCC in noncirrhotic liver has similar
angiogenic aspects as HCC in cirrhotic livers. Similarities
between the angiogenic characteristics of HCC in cirrhotic
and noncirrhotic livers could lend support to sorafenib
treatment for advanced HCC in noncirrhotic patients.
The aim of the present study was (1) to compare the
angiogenic status of HCC in cirrhotic and noncirrhotic
livers and (2) to correlate MVD with tumor-, patient-, and
radiological characteristics of HCC. To this end, we ana-
lyzed the dynamics of ECs in the tumor vessels in HCC by
the quantiﬁcation of MVD, by the apoptotic and prolifer-
ation rate of ECs in tumor microvessels, and by the tumor
vessel’s pericyte coverage, which is considered to be a sign
of mature vessels.
PATIENTS AND METHODS
Patients
A total of 70 anonymized HCC tumor specimens from
69 consecutive patients were analyzed according to recent
national guidelines. In 31 cases, HCC developed in cir-
rhotic livers, and these patients underwent a liver
transplantation (n = 30) or a local resection (n = 1). The
causes of the cirrhosis were HBV (n = 8) or HCV (n = 9),
cryptogenic cirrhosis (n = 5), primary biliary cirrhosis,
alcohol, autoimmune hepatitis, a1-antitrypsin deﬁciency
(n = 2 each), and biliary atresia (n = 1). In two additional
patients, each with a cirrhotic liver, biopsies of the HCC
were available for analysis. In the 30 liver explants, solitary
tumor nodules were found in 13 cases, 2 nodules were
found in 8 cases, 3 nodules in 3 cases, and the remaining 6
cases had more than 3 nodules. A representative sample of
1 nodule per case was obtained for the analysis. Another 35
cases developed HCC in normal, noncirrhotic, nonﬁbrotic
livers, and in none of these patients were HBV or HCV
antibodies detectable. All these patients underwent a partial
liver resection. In 1 patient, a recurrent HCC in a non-
cirrhotic liver was resected 16 months after a previous
local resection, and both tumors were included in the study.
The follow-up of this patient was calculated from her ﬁrst
operation. A tumor biopsy of another noncirrhotic patient
was added for analysis. In the noncirrhotic group, 29
patients had single tumor nodules. The remaining 6 patients
had more than 1 tumor nodule, and in those cases a rep-
resentative sample of 1 tumor nodule per case was obtained
for the analysis. None of the patients had undergone any
previous treatment for HCC. Of the 35 noncirrhotic
patients, 5 were excluded from the survival analysis
because of early (within 3 months) postoperative mortality
(n = 3) or because of noncurative resections (n = 2). Of
the 30 transplanted patients, 2 were excluded because of
early postoperative mortality. The follow-up for the
patients consisted of a-fetoprotein serum levels, thoracic
X-rays, and ultrasound examinations of the liver remnant
every 3 months during the ﬁrst 2 years after partial liver
resection and every 6 months thereafter, until 5 years after
the resection date. In case of suspicious ﬁndings, CT scans
of the thorax and abdomen were performed in order to
detect resectable recurrences. In cases of unresectable
recurrences, patients were treated with best supportive
care. In patients who had liver transplant, routine follow-up
was done according to our protocol, which included
ultrasound of the liver, a-fetoprotein serum levels, and
thoracic X-rays every 6 months.
Immunohistochemistry
Immunohistochemical staining with CD34 (clone Qbend
10, ready-to-use dilution, Immunotech, Marseille, France),
Ki 67 (DAKO, Glostrup, Denmark. 1:75), and anticleaved
caspase-3 (Cell Signaling Technology, Danvers, MA, 1:50)
was used on 4 lm parafﬁn sections. Single immunostain-
ing with anti-CD34 was performed to detect MVD in
the tumors. Double immunostaining of anti-CD34 and
anticleaved caspase-3 were performed as described previ-
ously.
12 Double immunostaining using anti-CD34 and anti-
Ki67 was performed after microwave antigen retrieval.
Sections were incubated with anti-Ki67 followed by
RAMPO/GARPO and DAB to develop the staining reac-
tion. After incubation with anti-CD34, GAMAP and Fast
Red were used for the staining reaction and hematoxylin
for nuclear counterstaining. Double immunostaining of
CD34/aSMA was performed to detect vascular pericyte
coverage in a method similar to the CD34/Ki67 double
labeling but without any prior antigen retrieval.
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Grading of HCC was done according to Edmondson and
Steiner and the growth patterns were identiﬁed as trabec-
ular, acinar, solid, and scirrhous. The Chalkley point
overlap morphometric technique was used for quantiﬁca-
tion of the MVD at three ‘‘hot spots’’ on the CD34-stained
sections, as described previously.
12,13 First, tumors were
scanned at low magniﬁcation to identify areas with high
MVD (‘‘hot spots’’). Then, at 9200 magniﬁcation, an
eyepiece graticule containing 25 randomly positioned dots
was rotated to reach the maximum number of points
overlapping with a CD34 positive structure, that is, the
vessels in the vascular ‘‘hot spot.’’ The number of over-
laying dots was counted. aSMA coverage of vessels was
calculated as the number of dots within or on the a-SMA-
positive vessels as a percentage of the total number of dots
overlaying CD34-positive structures. On CD34/Ki67 dou-
ble-stained sections, Ki67 labeling was determined in a
9400 microscopic ﬁeld, at the same 3 ‘‘hot spots’’ as used
for MVD counting. The vascular Ki67 labeling index (LI)
was deﬁned as the number of Ki67 ?/CD34 ? EC nuclei
per total number of ECs. The Ki67 LI of tumor cells was
obtained by counting the number of Ki67 positively stained
tumor cells per 300 individual tumor cells in each area. In
CD34/activated caspase-3 double-labeled sections, the
activated caspase-3 positive HCC cells and activated cas-
pase-3 positive ECs were calculated in three ‘‘hot spots’’
at 400 9 magniﬁcation. For each case, the apoptotic index
(AI) was calculated as the number of apoptotic cells 9
100/number of high-power ﬁelds.
Analysis of CT Images
Images were analyzed using the change in attenuation of
dynamic four-phase CT scanning during the arterial and
portal phase of contrast enhancement. Only the source data
of CT scans performed after 2002 were available for
analysis. The enhancement (in Hounceﬁeld units; HU) in
the tumor and the surrounding parenchyma was recorded.
In tumors with a heterogeneous enhancement, the most
hyperattenuating region was identiﬁed in order to obtain
the most reliable comparison with MVD, which was scored
in the vascular ‘‘hot spot.’’ The relative enhancement of the
tumor was compared with that of the surrounding paren-
chyma in the arterial and portal phases according to the
equation:
Relative enhancement ¼
HU tumor   HU parenchyma
HU parenchyma
  100%
The relative enhancement was correlated with MVD.
We chose for calculation of the relative enhancement to
eliminate interindividual differences in the contrast medium
enhancement in HCC tumor nodules versus the adjacent
parenchyma. This difference is highly dependent on various
factors including patients’ physiology, for example, the
cardiac output in the hyperdynamic circulation of cirrhotic
patients.
14
Statistics
The results of the vascular dynamics in cirrhotic versus
noncirrhotic HCCs were presented as medians with inter-
quartile ranges (IQR) and were compared using the Mann–
Whitney test. MVD in relation to tumor grade was ana-
lyzed using ANOVA. Categorical variables were analyzed
using the chi-square test or the Fisher exact test, where
appropriate. Survival analysis was performed using the
Kaplan–Meier method, with the log-rank test for compar-
ison. Median survival and 95% conﬁdence intervals (95%
CI) were given together with 5-year survival data. Pearson
correlation coefﬁcients were presented for data with a
normal distribution. Variables with a nonparametric dis-
tribution were log transformed in order to normalize the
data.
RESULTS
EC Apoptosis and Proliferation
EC apoptosis and proliferation are rare events in tumor
microvessels. In 31 of the 37 noncirrhotic HCCs and 29 of
the 33 cirrhotic HCCs, no apoptotic ECs were identiﬁed. In
the remaining tumors, apoptotic ECs could rarely be
identiﬁed (Fig. 1). EC proliferation was also rare in both
types of HCCs (Fig. 2). Nevertheless, the median number
(IQR) per high-power ﬁeld in noncirrhotic HCCs was
higher than in cirrhotic HCCs (Table 1, P = .011).
Similar MVD in HCCs in Cirrhotic versus Noncirrhotic
Livers
CD34 positive tumor vessels demonstrated a rather
uniform pattern of staining. A striking change in CD34
expression was visible at the interface of an HCC and
adjacent parenchyma (Fig. 3). In the parenchyma, sinu-
soids were faintly stained with a progressive increase in
staining intensity toward the tumor. Of note is the change
in morphology, with the sinusoids in the normal liver
demonstrating obvious lumina, whereas in the tumor itself
the vessel lumen was often slitlike and the vessels were
tortuous when a sinusoidal-like pattern was present.
Quantiﬁcation of MVD revealed no difference between
noncirrhotic and cirrhotic HCCs (Table 1).
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Because vascular invasion is an important adverse
prognostic variable, MVD was compared in tumors with
vascular invasion versus those without vascular invasion in
cirrhotic and noncirrhotic livers separately. The mean
MVD in cirrhotic HCCs was comparable in tumors with
vascular invasion versus those without vascular invasion
(Table 1). In noncirrhotic livers, tumors without vascular
invasion tended to have a lower MVD compared with
tumors with vascular invasion (P = .07, Table 1).
aSMA-Positive Cells
The majority of tumor microvessels are covered by
aSMA-positive cells. Microvessels that are double positive
for CD34 and aSMA were regarded to be mature vessels.
The median percentage (IQR) of CD34 ?/aSMA ? ves-
sels in noncirrhotic and cirrhotic HCCs was comparable
(Table 1). These numbers suggest that the majority of HCC
microvessels were stabilized, quiescent vessels.
Proliferation and Apoptosis in Tumor Cells
The proliferation rate of tumor cells in noncirrhotic
versus cirrhotic HCCs was no different (Table 1). The rate
of apoptotic tumor cells in general was low, despite the fact
that they could be easily identiﬁed if present (Fig. 1). The
median number of apoptotic tumor cells per high-power
ﬁeld in noncirrhotic livers was slightly different from that
in cirrhotic livers (Table 1).
MVD in Relation to Tumor and EC Characteristics
Of the 70 HCCs, 6 were graded as (Edmonson Steiner)
grade 1, 39 as grade 2, and 25 as grade 3. ANOVA with
post hoc comparisons revealed a signiﬁcant (P\.05) dif-
ference between MVD in grade 1 (mean 9.4, standard
deviation [SD] 2.8) versus in grade 2 (mean 13.1, SD 3.4)
HCCs.
MVD was not correlated with tumor size, with the rate
of tumor cell proliferation or apoptosis, or with the rate of
EC proliferation or apoptosis in tumor microvessels. In
addition, no correlation was encountered between MVD
and the number of aSMA-positive CD34-positive micro-
vessels (mature vessels).
MVD and Contrast Washout
MVD is negatively correlated with contrast washout but
is not correlated with contrast supply. In general, the
tumors were hyperintense in the arterial phase; the mean
number of HU in the tumor was 17% (range -56% to
?57%) higher compared with the surrounding paren-
chyma. No correlation (r =- .23, P = .52) was found
between MVD and the relative contrast enhancement of the
tumor during the arterial phase. In the portal phase, most of
the tumors were hypointense; the mean number of HU was
15% (range -35% to ?19%) lower than the surrounding
parenchyma. A negative correlation (r =- .75, P = .012)
was found between MVD and the enhancement of the
tumor in the portal phase. Thus, the higher the MVD in
the tumors the less contrast was present in the tumor during
the portal phase of contrast enhancement.
FIG. 1 Immunohistochemistry of hepatocellular carcinoma demon-
strating apoptosis in tumor microvessels. Apoptotic EC (black arrow)
within the tumor microvessel. Double immunolabeling: anti-CD34
(red), anti-activated caspase 3 (brown). Negative EC nucleus: blue
arrow. Apoptotic tumor cell: black arrowhead
FIG. 2 Immunohistochemistry of hepatocellular carcinoma demon-
strating proliferation in tumor microvessels. Double immunolabeling:
anti-CD34 (red), Ki67 (brown). Proliferating ECs (arrow) and
proliferating tumor cells (arrow head) are clearly visible
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First, we analyzed survival in cirrhotic and noncirrhotic
patients separately because of the major differences in the
patient and disease characteristics found in the 2 groups
(Table 1). Median survival in transplanted patients
(112 months) was better than in resected patients
(38 months, P = .036). The 5-year survival rates were
66.8% in transplanted patients and 44.3% in resected
patients. In order to analyze the impact of MVD on sur-
vival, we categorized MVD into ‘‘low’’ (\median MVD
value) and ‘‘high’’ values ([median MVD value). Survival
of patients with high-MVD tumors was compared with that
of patients with low-MVD tumors separately for trans-
planted and resected patients. Survival in transplanted
patients was no different in the low versus the high MVD
values (Fig. 4; Table 1). In contrast, in the resection group,
the median survival in patients with tumors with a high
MVD (58 months) was longer (P = .05) compared with
the median survival in patients with low-MVD tumors
(12.2 months, Fig. 4; Table 1).
DISCUSSION
In this study we analyzed the angiogenic characteristics
of HCC in cirrhotic versus noncirrhotic livers at three
different levels: quantiﬁcation of proliferation and apop-
tosis of ECs in tumor vessels at the cellular level,
quantiﬁcation of MVD at the tumor-tissue level, and
analysis of tumor vascularization as seen by contrast-
enhanced CT imaging. The main conclusion is that the
angiogenic characteristics of HCC in cirrhotic livers are to
a large extent similar to those in noncirrhotic livers.
Additionally, microvessels in both tumor types exhibit a
very low turnover rate and mainly have the characteristics
of stable mature vessels. Indirect evidence of angiogenic
activity could be provided by EC dynamics, for example,
proliferative activity and apoptosis. Our ﬁndings of a low
TABLE 1 Clinicopathological,
angiogenic and survival
characteristics in patients with
HCC in noncirrhotic versus
cirrhotic livers
Numbers represent median
values (interquartile range)
unless stated otherwise
Noncirrhotic HCC Cirrhotic HCC P value
Gender (male:female) 16:14 25:3 .001
Mean age (range) 58.9 (20–83) 50.2 (2–68) .06
No. of nodules 1/2–3/[3 26/2/2 8/10/10 \.0001
Size of largest tumor median (range) 13.0 (3.0–25.0) 2.7 (1.0–6.0) \.0001
a fetoprotein serum level median (range) 6.8 (3–93,933) 21.5 (2–16,000) [.6
Endothelial cell proliferation 0.03 (0.04) 0.02 (0.02) .011
MVD 13.0 (6.0) 11.3 (3.0) .46
MVD, mean (range)
Venous invasion 13.3 (6–22) .07
No venous invasion 10.9 (6–16)
Venous invasion 11.9 (8–19) .9
No venous invasion 11.8 (5–19)
% Mature vessels 79.0 (61.0) 63.0 (46.0) .27
% Tumor cell proliferation 5.8 (15.1) 5.0 (8.4) .23
Apoptotic tumor cells 0.33 (1.33) 0.0 (0.67) .09
Median survival, months (95% CI) 38 (11–65) 112 (60–165) .036
Low MVD 12.2 (5.4–19.0) .05
High MVD 58 (24.8–90.7)
Low MVD 112 (45.2–179.8)
High MVD Not reached
FIG. 3 Immunolabeling with CD34 (brown), staining the border of a
hepatocellular carcinoma with adjacent nontumorous liver paren-
chyma. The adjacent liver parenchyma (lower right-hand corner)
shows a very faint staining with a gradual increase in staining
intensity toward the tumor (upper left border)
1568 W. Zeng. et al.proliferative and low apoptotic rate in ECs, the presence of
a high aSMA coverage rate, and the absence of a positive
correlation between hypervascularity on imaging and
tumor MVD are compatible with a rather stable EC com-
partment in tumor vessels in HCCs, irrespective of the
presence of cirrhosis. These results are in agreement with
the ﬁndings of our previous study in which we quantiﬁed
gene and protein expression of VEGF-A, its receptors
VEGFR-1 and VEGFR-2, and the angiopoietin/Tie 2 sys-
tem in HCC of cirrhotic and noncirrhotic patients.
15 We
found no increase in VEGF-A levels, nor the characteristic
pattern of increased angiopoietin-2/Tie-2 concomitant with
decrease of angiopoietin-1, which is the usual proﬁle for
tumor angiogenesis as seen in highly angiogenic tumors,
for example, renal cell carcinoma.
15
Although angiogenic sprouting, that is, new capillary
bud formation from preexisting vessels, was initially
thought to be the main mechanism of new vessel forma-
tion, various other mechanisms for vascularization of
tumors were put forward.
16 In the extremely rich vascu-
larized liver, especially, the process of co-option of
preexistent vessels—sinusoids—might be a suitable
option.
17 Co-option is a process in which the tumor hijacks
(co-opts) preexistent vessels of the host tissue in order to
obtain vascularization for ongoing tumor growth and has
been demonstrated in metastatic brain tumors in mice.
18
A progressive increase in CD34 expression by hepatic
sinusoidal ECs parallels the progression from low-grade to
high-grade dysplastic nodules into frank HCC.
19 This
increased expression is considered to be a sign of angio-
genesis.
7,20–23 Another possibility, however, is that changes
in the environment (from normal hepatocytes to malignant
and premalignant cells) induce an altered phenotype of
ECs; increasing CD34 expression on ECs might represent a
bystander effect of changing inﬂuences from adjacent cells
or growth factors.
An analysis of the literature on the relationship between
MVD and survival is presented in Table 2, which mainly
presents data on patients with resected HCCs. It can be
concluded from this table that CD34 is the most widely
used antibody to identify microvessels and that the asso-
ciation between MVD in tumor microvessels and prognosis
is highly variable. Most reports have found that a high
MVD is associated with a poor prognosis; others found no
association and two (including ours) found a favorable
outcome in resected patients with high-MVD tumors.
These differences can probably be explained by differences
in the underlying causes of the liver disease in the reported
studies. In addition, conﬂicting results have been published
on the correlation between hypervascularity on contrast-
enhanced CT and MVD in HCC. In one study, a correlation
between MVD and arterial and portal phase contrast
enhancement was found, whereas others found no corre-
lation.
24–26 In the present study, we found no correlation
between MVD and contrast enhancement in the tumor in
the arterial phase and a negative correlation in the portal
phase. These ﬁndings suggest that a high MVD is associ-
ated more with rapid washout of contrast than with a large
arterial blood supply.
We found a remarkable difference in the relationship of
MVD to survival; no effect of MVD was found in patients
after liver transplantation, whereas patients with a high
MVD had a better prognosis after partial liver resection
than those with a low MVD. One possible explanation for
the fact that MVD does not relate to survival in trans-
planted patients could be that metastases most frequently
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FIG. 4 Overall survival of patients with HCC in noncirrhotic livers
after partial hepatectomy (left panel) or patients with HCC in cirrhotic
livers after liver transplantation (right panel), stratiﬁed according to
microvessel density (MVD). MVD is divided into values above and
below the median value
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metastatic propensity, the intrahepatic metastases are
removed during liver transplantation, whereas following
partial liver resection the remnant liver can harbor clini-
cally undetectable metastases that give rise to recurrences
in due time. Our ﬁnding that patients with HCC with a low
MVD have a worse prognosis after partial liver resection
might be explained by the well-established phenomenon of
a more aggressive behavior of hypoxic tumor cells.
27,28
Based on this, low-MVD HCCs might have a higher
fraction of hypoxic tumor cells resulting in a more
aggressive tumor cell population, with a greater chance of
intrahepatic metastases.
There are three main limitations to this study: ﬁrst, its
retrospective nature; second, the limited number of
patients, which could result in a type II error; and, third, the
fact that we analyzed clinically detectable—advanced—
HCCs and not early HCCs in which the angiogenic
dynamics might be different. However, the low incidence
of HCC in noncirrhotic livers hampers the acquisition of
large numbers of patients in a reasonable time span. In
addition, the intervention of angiogenesis using sorafenib is
only indicated in advanced HCC and, as such, the angio-
genic balance is relevant when examining advanced HCC.
In conclusion, we found a low EC proliferation rate, a
high aSMA coverage of vessels, and no correlation
between the arterial blood supply and MVD both in cir-
rhotic and noncirrhotic HCCs. It appears that the EC
compartment of HCC microvessels demonstrates a rather
low turnover rate and is comparable in cirrhotic and non-
cirrhotic HCC. Until now the effect of sorafenib has only
been proven in patients with advanced HCC, with a
background of liver cirrhosis. Given the rarity of HCC in
noncirrhotic liver, it will be difﬁcult to prove the efﬁcacy
of sorafenib in patients with noncirrhotic HCC in a ran-
domized trial. However, the results of the present study
suggest a similarity in angiogenic status of HCC in cir-
rhotic and noncirrhotic livers and, as such, support the use
of sorafenib in advanced HCC in noncirrhotic patients as
well.
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TABLE 2 Summary of published series on MVD and prognosis of HCC after resection or liver transplantation
Year of publication
and Author
Number
of patients
Therapy
a Microvessel
staining
b
Prognosis of patients
with high MVD
c
Correlation of
hypervascularity
and MVD
d
Correlation of high
VEGF and MVD
e
1997 Tanigawa
29 43 RES CD34 Poor (DFS/OS) NE NE
vWF
1998 El Assal
25 71 RES vWF Poor (DFS) 0 0
1999 Sun
30 78 RES CD34 Poor (DFS) NE NE
2002 Poon
21 100 RES CD34 Poor (DFS) NE NE
vWF Poor (DFS)
2004 Nanashima
31 81 RES CD34 Favorable (DFS/OS) NE NE
2005 Ho
32 86 RES CD34 Comparable (DFS) NE NE
CD105 Comparable (DFS)
2006 Yang
33 113 RES CD34 Comparable (OS) NE ?
CD105 Poor (OS)
2006 Zhang
34 82 LT CD34 Poor (DFS, univariate) NE ?
2007 Yao
35 105 RES CD34 Poor (DFS/OS) NE 0
CD105 Poor (DFS/OS) ?
Present series 32 RES CD34 Favorable (DFS/OS) 0 (art) – (portal) NE
30 LT CD34 Comparable (DFS/OS)
NE not evaluated
a Type of treatment for HCC. RES partial liver resection, LT liver transplantation
b Antibody used for detection of microvessels. vWF anti-von Willebrand factor (factor VIII), CD34 anti-CD34 antibody, CD105 anti-CD105
antibody
c Prognosis of patients with tumors with high MVD as compared to those with low MVD. DFS disease-free survival, OS overall survival
d Correlation of hypervascularity as seen on contrast enhanced CT or angiography with MVD. +/-/0, positive, negative or no correlation
e Correlation of vascular endothelial growth factor (VEGF) with MVD. +/-/0, positive, negative, or no correlation
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